Page last updated: 2024-08-24

naxagolide and Parkinson Disease

naxagolide has been researched along with Parkinson Disease in 17 studies

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19908 (47.06)18.7374
1990's6 (35.29)18.2507
2000's2 (11.76)29.6817
2010's1 (5.88)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adams, JR; Boileau, I; Furukawa, Y; Guttman, M; Houle, S; Kish, SJ; Payer, DE; Rusjan, P; Strafella, A; Tong, J; Wilson, AA; Zack, M1
Adams, JR; Boileau, I; Furukawa, Y; Guttman, M; Hornykiewicz, O; Houle, S; Kapur, S; Kish, SJ; Rusjan, P; Tong, J; Wilson, AA1
Ginovart, N; Ko, F; McCormick, P; Seeman, P; Willeit, M1
Guillén, J; Laguna, J; Luquin, MR; Martínez-Lage, JM; Obeso, JA1
Diederich, NJ; Goetz, CG1
Ahlskog, JE; Bailey, PA; Miller, PM; Muenter, MD1
Lawrence, MS; Redmond, DE1
Coleman, RJ; Marsden, CD; Quinn, NP; Traub, M1
Cedarbaum, JM; Clark, M; Green-Parsons, A; Toy, LH1
Coleman, RJ; Marsden, CD; Quinn, NP; Stahl, SM; Temlett, JA1
Bondi, JV; Coleman, RJ; Hichens, M; Lange, KW; Loper, AE; Marsden, CD; Quinn, NP; Stahl, SM1
Factor, SA; Sanchez-Ramos, JR; Weiner, WJ1
Barter, R; Koller, WC; Vetere-Overfield, B1
Calne, DB; Mak, E; Stoessl, AJ1
Baumann, G; Chin, L; Lieberman, A1
Ahlskog, JE; Bell, G; McManis, P; Muenter, MD1
Nashef, L; Rose, FC1

Reviews

1 review(s) available for naxagolide and Parkinson Disease

ArticleYear
Dopaminergic agonists in the treatment of Parkinson's disease.
    Neurologic clinics, 1992, Volume: 10, Issue:2

    Topics: Apomorphine; Bromocriptine; Dopamine Agents; Humans; Lactose; Lisuride; Methylcellulose; Oxazines; Parkinson Disease; Pergolide; Receptors, Dopamine

1992

Trials

2 trial(s) available for naxagolide and Parkinson Disease

ArticleYear
Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.
    Clinical neuropharmacology, 1991, Volume: 14, Issue:3

    Topics: Adult; Aged; Carbidopa; Delayed-Action Preparations; Dopamine Agents; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Oxazines; Parkinson Disease

1991
(+)-4-Propyl-9-hydroxynaphthoxazine (PHNO), a new dopaminomimetic, in treatment of parkinsonism.
    Lancet (London, England), 1985, Dec-14, Volume: 2, Issue:8468

    Topics: Adult; Aged; Clinical Trials as Topic; Dopamine; Double-Blind Method; Female; Humans; Male; Middle Aged; Oxazines; Parkinson Disease; Time Factors

1985

Other Studies

14 other study(ies) available for naxagolide and Parkinson Disease

ArticleYear
[¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders.
    Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Disruptive, Impulse Control, and Conduct Disorders; Dopamine; Dopamine Agents; Female; Humans; Male; Middle Aged; Oxazines; Parkinson Disease; Positron-Emission Tomography; Receptors, Dopamine D2; Receptors, Dopamine D3

2015
Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.
    Brain : a journal of neurology, 2009, Volume: 132, Issue:Pt 5

    Topics: Aged; Binding, Competitive; Carbon Radioisotopes; Case-Control Studies; Corpus Striatum; Dopamine; Dopamine Antagonists; Female; Globus Pallidus; Humans; Male; Middle Aged; Oxazines; Parkinson Disease; Positron-Emission Tomography; Raclopride; Receptors, Dopamine D3; Statistics, Nonparametric

2009
Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.
    Synapse (New York, N.Y.), 2005, Volume: 58, Issue:2

    Topics: Animals; Benzothiazoles; Binding, Competitive; Brain; Cells, Cultured; Cricetinae; Domperidone; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Humans; Mice; Neurons; Oxazines; Parkinson Disease; Pramipexole; Radioligand Assay; Rats; Receptors, Dopamine D2; Receptors, Dopamine D3; Synapses; Synaptic Transmission; Thiazoles; Tritium

2005
The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys.
    European journal of pharmacology, 1993, Apr-28, Volume: 235, Issue:2-3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Dopamine Agents; Excitatory Amino Acid Antagonists; Ibotenic Acid; Indoles; Macaca fascicularis; Motor Activity; Oxazines; Parkinson Disease; Phenanthridines; Quinoxalines; Receptors, AMPA; Receptors, Glutamate

1993
MPTP lesions and dopaminergic drugs alter eye blink rate in African green monkeys.
    Pharmacology, biochemistry, and behavior, 1991, Volume: 38, Issue:4

    Topics: Animals; Apomorphine; Blinking; Chlorocebus aethiops; Dopamine Agents; Haloperidol; Male; MPTP Poisoning; Oxazines; Parkinson Disease; Receptors, Dopamine; Substantia Nigra; Sulpiride

1991
Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.
    Journal of neurology, neurosurgery, and psychiatry, 1990, Volume: 53, Issue:2

    Topics: Adult; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusion Pumps; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Oxazines; Parkinson Disease; Psychomotor Performance

1990
Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation.
    Movement disorders : official journal of the Movement Disorder Society, 1990, Volume: 5, Issue:4

    Topics: Activities of Daily Living; Antiparkinson Agents; Brain; Carbidopa; Delayed-Action Preparations; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Oxazines; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D2

1990
A strategy for measuring the therapeutic properties of new antiparkinsonian drugs, such as +PHNO, in patients with on-off fluctuations.
    Clinical neuropharmacology, 1989, Volume: 12, Issue:1

    Topics: Adult; Aged; Antiparkinson Agents; Dopamine Agents; Drug Evaluation; Female; Humans; Male; Middle Aged; Oxazines; Parkinson Disease

1989
The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results.
    Movement disorders : official journal of the Movement Disorder Society, 1989, Volume: 4, Issue:2

    Topics: Administration, Cutaneous; Adult; Antiparkinson Agents; Dopamine Antagonists; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Oxazines; Parkinson Disease

1989
The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.
    Journal of neurology, neurosurgery, and psychiatry, 1989, Volume: 52, Issue:6

    Topics: Antiparkinson Agents; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Oxazines; Parkinson Disease

1989
Tremors in early Parkinson's disease.
    Clinical neuropharmacology, 1989, Volume: 12, Issue:4

    Topics: Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Oxazines; Parkinson Disease; Tremor

1989
MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.
    Clinical neuropharmacology, 1988, Volume: 11, Issue:3

    Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Dopamine Agents; Female; Humans; Hypromellose Derivatives; Lactose; Levodopa; Lisuride; Methylcellulose; Middle Aged; Nausea; Oxazines; Parkinson Disease; Pergolide; Psychomotor Performance; Receptors, Dopamine

1988
PHNO [(+)-4-propyl-9-hydroxynaphthoxazine]: a new and effective anti-Parkinson's disease agent.
    Neurology, 1988, Volume: 38, Issue:10

    Topics: Adult; Aged; Dopamine; Dopamine Agents; Female; Humans; Male; Middle Aged; Oxazines; Parkinson Disease

1988
Parkinson's disease: further steps forward.
    Gerontology, 1987, Volume: 33, Issue:6

    Topics: Adrenal Medulla; Adult; Animals; Dementia; Dopamine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurons; Oxazines; Parkinson Disease

1987